Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lung cancer, small cell
Trial Type:  Treatment
Results 1-25 of 75 for your search:
Start Over
Whole-Brain Radiation Therapy with or without Hippocampal Avoidance in Treating Patients with Limited Stage or Extensive Stage Small Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-CC003, NCI-2015-01548, NCT02635009
Three Different Radiation Therapy Regimens in Treating Patients with Limited-Stage Small Cell Lung Cancer Receiving Cisplatin or Carboplatin and Etoposide
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CALGB-30610, NCI-2009-00470, CALGB 30610/RTOG 0538, CDR0000588879, RTOG 0538, NCT00632853
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer [IMpower133]
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO30081, NCI-2016-01683, 2015-004861-97, NCT02763579
Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian)
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D419QC00001, NCI-2017-00703, 2016-001203-23, NCT03043872
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, 348360, P131392, NCT02054104
Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9525, NCI-2014-00461, 13-505, NCT02079740
Ipilimumab and Hypofractionated Stereotactic Body Radiation Therapy in Treating Patients with Advanced Solid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0882, NCI-2015-00042, NCT02239900
BMS-986012 in Relapsed/Refractory SCLC
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA001-030, NCI-2014-02596, 2014-002372-89, NCT02247349
Study of BMS-986158 in Subjects With Select Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA011-001, NCI-2016-01458, 2015-000324-29, NCT02419417
Olaparib and Temozolomide in Treating Patients with Recurrent Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-121, NCI-2015-01724, NCT02446704
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: G1T28-02, NCI-2015-01360, 2016-001583-11, NCT02499770
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: G1T28-03, NCI-2015-01365, 2016-004611-13, NCT02514447
ATR Kinase Inhibitor VX-970 and Topotecan Hydrochloride in Treating Patients with Previously Treated Lung, Ovarian, Cervical, Neuroendocrine, or Small Cell Cancers
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0150, NCI-2015-01398, 346215, P142115, NCT02487095
Cyclodextrin-based polymer-camptothecin CRLX101 and Olaparib in Treating Patients with Relapsed or Refractory Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0107, NCI-2016-00748, P152527, NCT02769962
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: D081KC00001, NCI-2016-01020, 2015-004005-16, NCT02734004
Plicamycin in Treating Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas, or Germ Cell Tumors with Pleuropulmonary Metastases
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0152, NCI-2016-01247, P152145, NCT02859415
Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2015-1380, NCI-2016-01991, NCT02748889
Ipilimumab, Nivolumab, and Thoracic Radiation Therapy in Treating Patients with Extensive-Stage Small Cell Lung Cancer after Chemotherapy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18914, NCI-2017-00285, NCT03043599
Trametinib and Erlotinib Hydrochloride in Treating Patients with Stage IV or Recurrent Lung Cancer with EGFR Activating Mutation
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: 15-098, NCI-2017-00542, NCT03076164
Cisplatin or Carboplatin and Etoposide With or Without Vandetanib in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer or High-Grade or Poorly Undifferentiated Neuroendocrine Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LUN06-113, NCI-2013-00309, 0712-21, 1011004344, IRUSZACT0083, NCT00613626
High Dose Rate Brachytherapy in Treating Patients with Endometrial, Cervical, Lung, Breast, or Prostate Cancer
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 to 90
Trial IDs: 09-C-0100, NCI-2013-01448, 090100, 302844, P08407, NCT00924027
Start Over